Clinical relevance of venlafaxine ER for generalized anxiety disorder
Psychiatry and Clinical Neurosciences · 2025
DOI: 10.1111/pcn.13924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry and Clinical Neurosciences, 2025. Verfasst von Itsuki Terao. Beteiligte Einrichtung: Department of Psychiatry, Ikokoro Clinic Nihonbashi, Tokyo, Japan. Hauptthemen laut MEDLINE: Venlafaxine Hydrochloride, Anxiety Disorders, Serotonin and Noradrenaline Reuptake Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 2 Literaturangaben.
Abstract (Originalsprache)
A randomized, double‐blinded, placebo‐controlled study by Otsubo et al. demonstrated a statistically significant effect of venlafaxine in patients with generalized anxiety disorder. However, the magnitude of improvement may have little clinical value. Methodological factors—including the exclusion of placebo responders, the inclusion of participants with comorbid depressive disorders, and a higher rate of discontinuation due to adverse events—further diminish the clinical significance of the findings. Overall, although venlafaxine achieved statistical efficacy, it may lack a clinically meaningful risk–benefit balance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Ikokoro Clinic Nihonbashi, Tokyo, Japan.
ORCID-Profile: Itsuki Terao
Zitieren
APA
Terao, I. (2025). Clinical relevance of venlafaxine ER for generalized anxiety disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13924
Vancouver
Terao I. Clinical relevance of venlafaxine ER for generalized anxiety disorder. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13924
BibTeX
@article{Terao2025,
author = {Terao, Itsuki},
title = {Clinical relevance of venlafaxine ER for generalized anxiety disorder},
journal = {Psychiatry and Clinical Neurosciences},
year = {2025},
doi = {10.1111/pcn.13924}
}
EUVIMED